Comparative Look at Intravenous Iron Agents: Pharmacology, Efficacy, and Safety of Iron Dextran, Iron Saccharate, and Ferric Gluconate

Sunder‐Plassmann, Gere; Hörl, Walter H.

doi:10.1046/j.1525-139x.1999.99030.x

Cited by 14 publications

(10 citation statements)

References 43 publications

(52 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors concluded that a slower rate of infusion might be warranted. Similarly, Sunder‐Plassmann and Horl (29) recently recommended a maximum dose for iron saccharate of 100–200 mg.…”

Section: Iron Sucrose (Iron Saccharate)mentioning

confidence: 99%

The Comparative Safety of Intravenous Iron Dextran, Iron Saccharate, and Sodium Ferric Gluconate

Fishbane

Kowalski

2000

Seminars in Dialysis

100

View full text Add to dashboard Cite

Intravenous iron treatment is an important component of anemia therapy for patients on dialysis. Until recently iron dextran was the only parenteral form of iron available in the United States. This drug has been associated with occasional serious adverse reactions, including full-blown anaphylaxis. In 1999 the Food and Drug Administration approved a second form of iron for intravenous administration, sodium ferric gluconate in sucrose. It is expected that by the time of this publication, a third agent, iron saccharate will also be approved. In this review the comparative safety of these three agents is critically evaluated.

show abstract

Section: Iron Sucrose (Iron Saccharate)mentioning

confidence: 99%

The Comparative Safety of Intravenous Iron Dextran, Iron Saccharate, and Sodium Ferric Gluconate

Fishbane

Kowalski

2000

Seminars in Dialysis

100

View full text Add to dashboard Cite

show abstract

“…The IV route is preferred because oral iron is poorly absorbed and usually inadequate to correct anemia 1 . The administration of IV iron increases the bioavailability of iron for hemoglobin synthesis; however, it is given in doses vastly exceeding ordinary intake 2 . Because iron elimination is somewhat limited in HD patients, occurring mainly via intradialytic losses and vascular‐access‐related bleeding, there is a concern that a progressive positive iron balance may develop.…”

Section: Introductionmentioning

confidence: 99%

“…The Dialysis Outcomes Quality Initiative (DOQI) guidelines on anemia management define the following three iron storage states: iron deficiency (TSAT < 20% and ferritin < 100 ng/mL); functional iron deficiency (TSAT < 20% and ferritin > 100 ng/mL); and iron‐replete state (TSAT > 20% and ferritin > 100 ng/mL) 11 . Although in some studies, a high ferritin level has been associated with a higher risk of bacterial infection in HD patients , 2 no analysis of the DOQI iron storage targets has been published.…”

Section: Introductionmentioning

confidence: 99%

Iron storage indices and risk of bacterial infections in hemodialysis patients

Teehan¹,

Ruthazer

Balakrishnan³

et al. 2004

Hemodialysis International

View full text Add to dashboard Cite

show abstract

“…In recent years several papers have been published describing the effectiveness and safety of iron supplementation with iron gluconate or iron sucrose in patients with renal failure [5,6]. There is an opinion that both iron gluconate and iron sucrose are free of risk of the anaphylactic reaction, which may happen during use of iron dextran [7,8]. However results of the recent in vitro studies show that iron sucrose is more cytotoxic than iron gluconate or iron dextran, although it induces weaker oxidative stress [9].…”

Section: Introductionmentioning

confidence: 99%